The North America cancer tissue diagnostics market is expected to reach US$ 1,587.38 Mn in 2027 from US$ 923.79 Mn in 2018. The market is estimated to grow with a CAGR of 6.5% from 2019-2027.
The growth of the market is driven by the factors such as, growing cancer prevalence in North American region and new product launches & FDA approvals. However, the market is likely to slower down its growth due to the lack of reimbursement policies for cancer diagnosis in the region.
๐ ๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐
๐๐จ๐ฉ๐ฒ@ https://www.businessmarketinsights.com/sample/TIPRE00006459
Frequent FDA approvals and product launches fuel the growth of the market for cancer tissue diagnostics. Most of the major market players are involved in the manufacturing wide range of cancer diagnostics products that offer maximum advantages and early diagnosis. For instance, in June 2019, Agilent Technologies Inc. received the U.S. Food and Drug Administration (FDA) approval for its PD-L1 IHC 22C3 pharmDx assay. The assay is approved to aim in identifying patients with head and neck squamous cell carcinoma (HNSCC) for treatment with KEYTRUDA (pembrolizumab), anti-PD-1 therapy manufactured by Merck. Furthermore, In March 2018, Agilent Technologies Inc. launched a new color for immunohistochemistry: HRP Magenta for Dako Omnis. The latest staining characteristics of the chromogen will help it for the assessment of skin and lung tissue. Thus, the constant developments in technology in diagnostics along with, FDA approvals accelerate the market growth during the forecast period.
US is expected to lead the market in the North America region owing to increasing prevalence of cancer, improved diagnosis and treatment of the condition along with the advancements made by market players. Moreover, the country has several hospitals, super specialty hospitals which offers diagnostic and treatment services for the cardiovascular diseases. Therefore, considering the above mentioned factors the growth of the market in the country is likely to contribute largest share in the North America region during the forecast period.
๐๐
๐ฎ๐ฅ๐ฅ ๐๐๐ฉ๐จ๐ซ๐ญ ๐๐ข๐ง๐ค @ https://www.businessmarketinsights.com/reports/north-america-cancer-tissue-diagnostics-market
๐๐ก๐ ๐๐ข๐ฌ๐ญ ๐จ๐ ๐๐จ๐ฆ๐ฉ๐๐ง๐ข๐๐ฌ
F. Hoffmann-La Roche Ltd
Thermo Fisher Scientific Inc.
Bio Rad Laboratories Inc.
Abbott
Enzo Life Sciences, Inc.
Agilent Technologies, Inc.
Cancer Genetics Inc.
Merck KGaA (Sigma-Aldrich Co. LLC)
Danaher Corporation
Abcam plc
North America Cancer Tissue Diagnostics Market
The North America Cancer Tissue Diagnostics market is a rapidly evolving sector within the global healthcare industry. This market primarily involves the use of advanced diagnostic tools and techniques to detect and diagnose various forms of cancer in tissue samples. The rise in the prevalence of cancer, along with advancements in technology, is driving significant growth in the cancer tissue diagnostics market. In North America, particularly in the United States and Canada, there is a strong focus on improving diagnostic accuracy, expanding access to testing, and enhancing treatment outcomes for patients.
Market Overview
Cancer is one of the leading causes of death in North America. According to the American Cancer Society, an estimated 1.9 million new cancer cases are expected to be diagnosed in the United States in 2025, with nearly 600,000 deaths from the disease. This highlights the urgent need for effective and timely diagnostic tools that can accurately detect cancer at various stages of progression. Tissue diagnostics, including techniques like immunohistochemistry (IHC), in situ hybridization (ISH), and molecular diagnostics, play a pivotal role in identifying the presence of cancer and providing information that can guide treatment decisions.
ย Competitive Landscape
The North America Cancer Tissue Diagnostics market is highly competitive, with numerous players involved in developing and offering innovative diagnostic solutions. Leading companies include Roche Diagnostics, Abbott Laboratories, Thermo Fisher Scientific, Agilent Technologies, and Siemens Healthineers. These companies invest heavily in research and development (R&D) to introduce new products and technologies that can improve diagnostic accuracy, efficiency, and patient outcomes.
Furthermore, several startups and smaller companies are also entering the market with novel technologies and products aimed at improving tissue diagnostics. These companies often focus on specific niches within the market, such as developing more precise genetic testing or offering digital pathology solutions.
Challenges
Despite the growing market, several challenges remain. The high cost of advanced diagnostic tools can limit accessibility, particularly in developing regions. Moreover, there is a need for standardized protocols and regulatory approval processes for new technologies, which can slow down the introduction of innovative diagnostic solutions. Additionally, the complexity of certain diagnostic tests may require specialized training for healthcare professionals, further complicating the widespread adoption of these technologies.
๐๐๐จ๐ฎ๐ญ ๐๐ฌ:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications
The list Of Companies-
3D and 4D Technology Market- https://www.openpr.com/news/3921417/3d-and-4d-technology-market-segments-opportunities-regional
Last Mile Delivery Market- https://www.openpr.com/news/3921138/last-mile-delivery-market-global-analysis-size-share
Europe Barbeque Grill Market- https://www.openpr.com/news/3921830/europe-barbeque-grill-market-segments-opportunities